Drug intelligence / Profile preview

EB-104 (Elastin Biosciences)

Development stage: Preclinical
Lead developer: Elastin Biosciences
Modality: Small Molecules

Overview

EB-104 is a small molecule drug candidate developed by Elastin Biosciences, currently in the IND-enabling phase for the treatment of cardiovascular diseases. Identified through a cheminformatics-based platform, EB-104 is designed to restore the structural integrity of tissues by boosting the production of elastin and fortifying the elastin-based extracellular matrix. The therapeutic approach focuses on reversing or halting the degradation of elastin, a critical component for the elasticity and resilience of cardiovascular tissues. As of early 2024, EB-104 has successfully completed proof-of-concept studies.

Targets

CD19 (B lymphocyte antigen CD19)CD22 (Cluster of Differentiation 22)

Beyond the preview

Go deeper on EB-104 (Elastin Biosciences).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EB-104 (Elastin Biosciences).